BAYN Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.42 |
| 52 Week High | €67.49 |
| 52 Week Low | €46.70 |
| Beta | 1.15 |
| 1 Month Change | -10.61% |
| 3 Month Change | -5.18% |
| 1 Year Change | -19.77% |
| 3 Year Change | -16.45% |
| 5 Year Change | -47.16% |
| Change since IPO | 292.23% |
Recent News & Updates
Recent updates
Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky
Dec 07
Is Bayer (ETR:BAYN) A Risky Investment?
Aug 18Results: Bayer Aktiengesellschaft Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Bayer (ETR:BAYN) Has A Somewhat Strained Balance Sheet
Mar 02These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Oct 31Bayer (ETR:BAYN) Has A Somewhat Strained Balance Sheet
Jul 18Should You Buy Bayer Aktiengesellschaft (ETR:BAYN) For Its 3.7% Dividend?
May 03Does Bayer (ETR:BAYN) Have A Healthy Balance Sheet?
Mar 11Bayer's(ETR:BAYN) Share Price Is Down 45% Over The Past Three Years.
Feb 13How Does Bayer Aktiengesellschaft (ETR:BAYN) Fare As A Dividend Stock?
Jan 17What Kind Of Investors Own Most Of Bayer Aktiengesellschaft (ETR:BAYN)?
Dec 13Is Bayer (ETR:BAYN) A Risky Investment?
Nov 22Shareholder Returns
| BAYN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -0.01% | -1.3% |
| 1Y | -19.8% | -12.7% | -8.5% |
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned -12.7% over the past year.
Return vs Market: BAYN underperformed the German Market which returned -8.5% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: BAYN is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BAYN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 101,735 | Werner Baumann | https://www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market Cap | €53.39b |
| Earnings (TTM) | €3.04b |
| Revenue (TTM) | €50.49b |
17.3x
P/E Ratio1.0x
P/S RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €50.49b |
| Cost of Revenue | €19.44b |
| Gross Profit | €31.05b |
| Other Expenses | €28.01b |
| Earnings | €3.04b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 08, 2023
| Earnings per share (EPS) | 3.09 |
| Gross Margin | 61.49% |
| Net Profit Margin | 6.02% |
| Debt/Equity Ratio | 105.6% |
How did BAYN perform over the long term?
See historical performance and comparison